Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) received written notice from MyoKardia, Inc. for the termination of the collaboration and license agreement dated July 20, 2020.

Under the agreement, Fulcrum had granted MyoKardia an exclusive worldwide license to discover, develop, and commercialize novel targeted therapies for genetic cardiomyopathies.

Also Read: Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial

Under the agreement, under a mutually agreed research plan, Fulcrum agreed to perform assay screening and related research activities to identify and …

Full story available on Benzinga.com